Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
Go back to Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 57.67 -1.34 (2.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.01 | 52 Week High | $17.00 | |||
| Open | $58.97 | 52 Week Low | $3.55 | |||
| Day High | $59.41 | P/E | N/A | |||
| Day Low | $57.55 | EPS | $-1.33 | |||
| Volume | 2,538,923 | |||||
| SPDR S&P INTERNATIONAL INDUSTRIAL SECTOR (NYSE: IPN) | Delayed: 34.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.71 | 52 Week High | $30.88 | |||
| Open | $0.00 | 52 Week Low | $24.64 | |||
| Day High | $34.71 | P/E | N/A | |||
| Day Low | $34.71 | EPS | $0.00 | |||
| Volume | 741,680 | |||||
| Ipsen S.A. Sponsored ADR (AMEX: IPSEY) | Delayed: 45.91 -3.24 (6.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $49.15 | 52 Week High | $17.79 | |||
| Open | $45.91 | 52 Week Low | $13.01 | |||
| Day High | $45.91 | P/E | N/A | |||
| Day Low | $45.91 | EPS | $0.00 | |||
| Volume | 10,276 | |||||
